Relmada Therapeutics, Inc. (RLMD)
NASDAQ: RLMD · Real-Time Price · USD
0.450
-0.070 (-13.44%)
At close: Jan 2, 2025, 4:00 PM
0.473
+0.023 (5.09%)
After-hours: Jan 2, 2025, 7:53 PM EST
Relmada Therapeutics Stock Forecast
RLMD's stock price has decreased by -88.66% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 4 analysts with 12-month price forecasts for RLMD stock have an average target of 4.25, with a low estimate of 1.00 and a high estimate of 13. The average target predicts an increase of 844.23% from the current stock price of 0.45.
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for RLMD stock from 4 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 2 | 2 | 2 | 2 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho | Mizuho | Buy → Hold Downgrades $23 → $1 | Buy → Hold | Downgrades | $23 → $1 | +122.17% | Dec 5, 2024 |
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $10 → $1 | Buy → Hold | Downgrades | $10 → $1 | +122.17% | Dec 4, 2024 |
| Jefferies | Jefferies | Hold → Strong Buy Upgrades $3.5 → $13 | Hold → Strong Buy | Upgrades | $3.5 → $13 | +2,788.25% | Sep 17, 2024 |
| Goldman Sachs | Goldman Sachs | Hold → Strong Sell Downgrades $3 → $2 | Hold → Strong Sell | Downgrades | $3 → $2 | +344.35% | Jun 5, 2024 |
| Mizuho | Mizuho | Strong Buy Reiterates $26 | Strong Buy | Reiterates | $26 | +5,676.49% | Jun 15, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.79
from -3.28
EPS Next Year
-1.17
from -2.79
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | 31.5M | |||
| Avg | n/a | n/a | 10.2M | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -2.81 | -0.16 | -0.05 | |||
| Avg | -2.79 | -1.17 | -1.65 | |||
| Low | -2.72 | -2.14 | -3.04 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.